ESMO World Congress on Gastrointestinal Cancer 2017

Oncology Meeting Resources

28 Jun - 01 Jul 2017, Barcelona, Spain

ESMO World GI 2017 square image

The ESMO World Congress on Gastrointestinal Cancer 2017 (World GI) is the premier global event in the field, encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours.

Abstracts, presentations and webcasts are open access. The use of these presentations is for personal educational purposes only. ESMO thanks the authors for their generosity.

Watch the ESMO scientific videos

Best Abstracts Session on Colorectal Cancer, Speaker: Filippo Pietrantonio

Tips for Practice: MSI Testing in GI Cancers, Speaker: Fatima Carneiro

Prevention of Colorectal Cancer, Speaker: Nadir Arber

The Role of Microbiome in Cancer Medicine, Speaker: James Godaert

All interviews from the event on the ESMO Channel





Format available

https://oncologypro.esmo.org/Meeting-Resour...rognostic-biomarkers-in-colon-adenocarcinoma

Long non-coding RNAs (lncRNAs) have important biological functions and can be used as prognostic biomarkers in cancer. To identify a lncRNA as prognostic signature in colon adenocarcinoma (COAD).

Date: 28 Jun 2017
Presenter: Yujie Yuan
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer

https://oncologypro.esmo.org/Meeting-Resour...-from-eastern-Algeria-with-colorectal-cancer

Cancer is increasingly a major public health problem in Algeria, where the number of cases and the proportions vary from one region to another (the East: 28%). Colorectal cancer is the third most common cancer in Algeria both sexes combined.

Date: 28 Jun 2017
Presenter: Djedi Hanene
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...rinotecan-The-phase-II-CRICKET-study-by-GONO

Clinical benefit from rechallenge with cetuximab based therapy in KRAS wild-type mCRC patients previously treated with the same anti-EGFR-based regimen was suggested in a retrospective study.

Date: 28 Jun 2017
Presenter: Daniele Santini
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer, Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...lorectal-cancer-A-study-in-Algerian-patients

Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. More than 30% patients present with metastases at diagnoses and will require systemic chemotherapy.

Date: 28 Jun 2017
Presenter: Said Belhadef
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer, Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...tasis-in-advanced-colorectal-cancer-patients

To date, published studies have failed to demonstrate a predictive role of PD-1/PD-L1 immunostainings in metastatic (met) colorectal cancer (mCRC) patients (pts) submitted to immunotherapy.

Date: 28 Jun 2017
Presenter: Enrico Falco
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...s-from-colorectal-cancer-A-multicenter-study

Surgical treatment of hepatic or pulmonary metastasis is the optimal therapeutic goal in metastatic colorectal cancer. We aim to analyze prognostic factors and outcome differences between resected liver limited vs lung limited metastases.

Date: 28 Jun 2017
Presenter: Haifa Rachdi
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...ncer-via-modulation-of-CXCR2-and-av-integrin

Peritoneal carcinosis (PC) is the third common site of metastatic colorectal cancer which characterized by a very low survival rate. Surgical trauma has been identified as an important factor in the...

Date: 28 Jun 2017
Presenter: Mattias lepsenyi
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...enteric-artery-of-colorectal-cancer-patients

In recent years, nitric oxide (NO) and hydrogen sulfide (H2S) previously considered to be potentially toxic chemicals, have been established that have roles in cancer progression and prevention.

Date: 28 Jun 2017
Presenter: Ismail Maulood
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer

https://oncologypro.esmo.org/Meeting-Resour...er-CRC-and-self-expandable-metal-stents-SEMS

CRC can present with malignant bowel obstruction (MBO) in 7-30% of cases. Conventional therapies have high rates of morbidity and mortality in emergency conditions.

Date: 28 Jun 2017
Presenter: Rebeca Mondéjar Solís
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer, Cancer Immunology and Immunotherapy

https://oncologypro.esmo.org/Meeting-Resour...colorectal-cancer-New-insights-in-probiotics

Colorectal cancer remains among the leading causes of cancer death across the globe. Unfortunately, its management following the standard chemotherapy is not completely satisfying and an alternative...

Date: 28 Jun 2017
Presenter: Nitin Bhandari
Resources: Abstract
Topics: Gastrointestinal Cancers, Colon Cancer, Rectal Cancer